1-[2-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl-methylamino]ethyl]-3-[(4-methylphenyl)methyl]urea | 1381760-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-[2-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl-methylamino]ethyl]-3-[(4-methylphenyl)methyl]urea
• CAS: 1381760-87-7
• 化学式: C₂₅H₃₄N₈O₄
• 分子量: 510.596
• InChiKey: WTRBQFBMZUJRFL-ZDXOVATRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1-[2-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl-methylamino]ethyl]-3-[(4-methylphenyl)methyl]urea 在 水 、 三氟乙酸 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以73%的产率得到1-[2-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylamino]ethyl]-3-[(4-methylphenyl)methyl]urea
  参考文献：
  名称：

  [EN] MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF
  [FR] MODULATEURS D'HISTONE MÉTHYLTRANSFÉRASE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2012082436A3
• 作为产物：
  描述：

  benzyl N-[2-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl-methylamino]ethyl]carbamate 在 palladium 10% on activated carbon 氢气 、 对硝基苯基氯甲酸酯 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 0.5h， 生成 1-[2-[[(3aR,4R,6R,6aR)-4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl-methylamino]ethyl]-3-[(4-methylphenyl)methyl]urea
  参考文献：
  名称：

  [EN] MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF
  [FR] MODULATEURS D'HISTONE MÉTHYLTRANSFÉRASE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2012082436A3

文献信息

• Modulators of Histone Methyltransferase, and Methods of Use Thereof
  申请人：Epizyme, Inc.

  公开号：US20160068559A1

  公开（公告）日：2016-03-10

  Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.

  本发明涉及一种化合物、含有该化合物的药物组合物，以及将该化合物和组合物用作组蛋白甲基转移酶调节剂，以及治疗受组蛋白甲基转移酶活性调节影响的疾病的用途。
• Combination Therapy for Treating Cancer
  申请人：Epizyme, Inc.

  公开号：US20140323421A1

  公开（公告）日：2014-10-30

  The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
• DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA
  申请人：EPIZYME, INC.

  公开号：US20150342979A1

  公开（公告）日：2015-12-03

  The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
• COMBINATION THERAPY FOR TREATING CANCER
  申请人：EPIZYME, INC.

  公开号：US20160045531A1

  公开（公告）日：2016-02-18

  The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
• INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF
  申请人：Epizyme, Inc.

  公开号：US20170137455A1

  公开（公告）日：2017-05-18

  The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.